{ "items": [ "\n\n
\n \n\n \n \n \n \n MORU Bangkok\n \n \n\n \n\n\n
\n \n\n \n21 July 2021
\n \n \n \nAn international team, led by Phaik Yeong Cheah, conducted an anonymous online survey from May-June 2020, asking 5,058 people in Thailand, Malaysia, United Kingdom, Italy and Slovenia to share their experiences. Anne Osterrieder and colleagues report the unequal impacts of public health measures, and the prevalence of \u2018fake news\u2019.
\n \n\n \n \n\n \n\n \n \n \n \n COPCOV\n \n \n \n \n COVID-19\n \n \n \n \n MORU Bangkok\n \n \n\n \n\n\n
\n \n\n \n9 July 2021
\n \n \n \nAs high COVID-19 daily cases and highly transmissible variants risk overwhelming countries\u2019 healthcare systems, COPCOV, the world\u2019s last-standing large prophylaxis RCT, faces tight timelines to determine whether chloroquine/ hydroxychloroquine prevents COVID-19
\n \n\n \n \n\n \n\n \n \n \n \n MORU Bangkok\n \n \n\n \n\n\n
\n \n\n \n8 July 2021
\n \n \n \nAbout one-third of children diagnosed with severe malaria may instead have an alternative cause of illness, but simple blood tests could help researchers distinguish between the two and speed up research on new treatments.
\n \n\n \n \n\n \n\n \n \n \n \n MORU Bangkok\n \n \n \n \n Video\n \n \n\n \n\n\n
\n \n\n \n8 June 2021
\n \n \n \nMalaria continues to be a major killer, particularly in sub-Saharan Africa, affecting the world\u2019s most vulnerable populations with more than 500,000 deaths per year, most of them African children. Emergence of resistance to antimalarial drugs is major public health issue. American Society for Microbiology Editor Dr Cesar Arias discusses with Professor Sir Nick White the latest information on this rapidly evolving field.
\n \n\n \n \n\n \n\n \n \n \n \n MORU Bangkok\n \n \n\n \n\n\n
\n \n\n \n19 May 2021
\n \n \n \nWhich infections are most common in the Chiangrai region? How should we treat them and how can we improve diagnostic? Which strategies are most effective in directing antibiotic treatment? Blog by Carlo Perrone, research physician based at the Chiang Rai Clinical Research Unit in Chiangrai, Thailand.
\n \n\n \n \n\n \n\n \n \n \n \n Awards & Appointments\n \n \n \n \n MORU Bangkok\n \n \n \n \n SMRU\n \n \n\n \n\n\n
\n \n\n \n12 May 2021
\n \n \n \n\"Although it is hard to look beyond the pandemic right now,\" says President of the Academy of Medical Sciences Professor Dame Anne Johnson, \"I want to stress how important it is that the Academy Fellowship represents the widest diversity of biomedical and health sciences. The greatest health advances rely on the findings of many types of research, and on multidisciplinary teams and cross-sector and global collaboration.\"
\n \n\n \n \n\n \n\n \n \n \n \n MORU Bangkok\n \n \n \n \n Public Engagement\n \n \n\n \n\n\n
\n \n\n \n7 May 2021
\n \n \n \nLive and on-line from Bangkok! Be ready for Thursday 13th May, when Pint of Science Thailand will stream live from Bangkok. Join us via Facebook, YouTube or right here from the Pint of Science Thailand website as we journey from bacterial infections to viruses, discover how clinical trials work, and how scientific development is seen in the eyes of the law!
\n \n\n \n \n\n \n\n \n \n \n \n MORU Bangkok\n \n \n \n \n Public Engagement\n \n \n\n \n\n\n
\n \n\n \n25 April 2021
\n \n \n \nFor World Malaria Day 2021, F1000 Research Blog spoke to Professor Phaik Yeong Cheah about her research focussed on drama and arts-based community engagement for malaria research, published with Wellcome Open Research.
\n \n\n \n \n\n \n\n \n \n \n \n MORU Bangkok\n \n \n\n \n\n\n
\n \n\n \n23 April 2021
\n \n \n \nOn Sunday 25 April, World Malaria Day, the Developing Paediatric Primaquine (DPP) project will launch its website. DPP will produce children-appropriate primaquine doses that could both cut malaria deaths in vulnerable African children by blocking transmission of P. falciparum malaria and reduce P. vivax malaria more widely.
\n \n\n \n \n\n \n\n \n \n \n \n MORU Bangkok\n \n \n\n \n\n\n
\n \n\n \n19 March 2021
\n \n \n \nMillions of children weighing less than 15kg are currently denied access to Ivermectin treatment due to insufficient safety data being available to support a change to the current label indication. The WorldWide Antimalarial Resistance Network\u2019s new meta-analysis provides evidence that supports removing this barrier and improving treatment equity.
\n \n\n \n \n\n \n\n \n \n \n \n MORU Bangkok\n \n \n\n \n\n\n
\n \n\n \n16 March 2021
\n \n \n \nThe Medicine Quality Research Group has published a new Medical Product Quality Report focussing on increasing issues around substandard and falsified (SF) COVID-19 vaccines. With the implementation of the key innovations of COVID-19 vaccines, there have been growing numbers of reports of SF vaccines in the public domain. Given the vital role they will play in ending the pandemic and protecting the global population but severe issues with equitable access, SF vaccines are highly likely to be a growing problem.
\n \n\n \n \n\n \n\n \n \n \n \n MORU Bangkok\n \n \n\n \n\n\n
\n \n\n \n12 February 2021
\n \n \n \nEvidence from a new study, initiated by the Primaquine Roll Out Group and conducted at WWARN, supports the World Health Organization (WHO) recommendation for use of 0.25mg/kg dose of primaquine (PQ) combined with artemisinin-based combination therapies (ACT) to block Plasmodium falciparum transmission.
\n \n\n \n \n\n \n\n \n \n \n \n MORU Bangkok\n \n \n\n \n\n\n
\n \n\n \n4 February 2021
\n \n \n \nThe Indonesian government policy to exclude the elderly in the first phase of the COVID-19 vaccination program could hinder the vaccine\u2019s impact in lowering mortality rates. COVID-19 mortality rates in Indonesia, the highest in Southeast Asia, are dominated by those in the 60 years and above age bracket. In this article published in The Conversation, Kartika Saraswati and fellow DPhil students elaborate how, by prioritising vaccination for elderly, Indonesia may optimally reduce the hospital burden and COVID-19 deaths amidst a limited vaccine supply during the first vaccination phase.
\n \n\n \n \n\n \n\n \n \n \n \n MORU Bangkok\n \n \n\n \n\n\n
\n \n\n \n13 January 2021
\n \n \n \nA study to explore the variations of how microscopy methods are reported in published malaria studies has recommended standardised procedures should be implemented for methodological consistency and comparability of clinical trial outcomes.
\n \n\n \n \n\n \n\n \n \n \n \n Awards & Appointments\n \n \n \n \n MORU Bangkok\n \n \n\n \n\n\n
\n \n\n \n16 December 2020
\n \n \n \nSusie Dunachie joins a prestigious group of leading health researchers in the latest cohort of NIHR Global Research Professors. These awards fund research leaders of the future to promote effective translation of research and to strengthen health, public health and care research leadership at the highest academic levels. Research conducted by Global Research Professors directly benefits people in LMICs. A Consultant in Infectious Diseases and Medical Microbiology, Susie works on the development of a vaccine to prevent death from melioidosis in people with type 2 diabetes mellitus in LMICs, and supports vaccine research in Thailand. Congratulations!
\n \n\n \n \n\n \n\n \n \n \n \n MORU Bangkok\n \n \n\n \n\n\n
\n \n\n \n7 December 2020
\n \n \n \nBlog by Rima Shretta. Preliminary efficacy results from three vaccine candidates currently in Phase 3 trials have shown an efficacy of more than 90% against the development of symptomatic COVID-19. While these results are promising, all vaccines are in relatively early stages of testing. A comprehensive and transparent roadmap is urgently needed, to determine how limited doses of the first vaccines to be licensed will be distributed, together with which groups will initially be prioritized.
\n \n\n \n \n\n \n\n \n \n \n \n MORU Bangkok\n \n \n\n \n\n\n
\n \n\n \n1 December 2020
\n \n \n \nA new study quantifying the high risk of Plasmodium vivax parasitaemia after treatment of Plasmodium falciparum malaria aims to identify populations in which a policy of universal radical cure, combining artemisinin-based combination therapy with a hypnozoitocidal antimalarial drug, would be most beneficial.
\n \n\n \n \n\n \n\n \n \n \n \n COVID-19\n \n \n \n \n MORU Bangkok\n \n \n\n \n\n\n
\n \n\n \n5 November 2020
\n \n \n \nIn the next few months, the first Phase 3 COVID-19 vaccine trials \u2013 the majority of them in upper-middle or high-income countries and in specific target populations like young adults \u2013 will report their results. How relevant will their study results be for low-resource settings?
\n \n\n \n \n\n \n\n \n \n \n \n Awards & Appointments\n \n \n \n \n LOMWRU\n \n \n \n \n MORU Bangkok\n \n \n\n \n\n\n
\n \n\n \n30 October 2020
\n \n \n \nThe University of Oxford has awarded CTMGH two new Professors. Elisabeth Ashley - UK-trained physician who specialises in infectious diseases and medical microbiology & virology, and Director of the Lao-Oxford-Mahosot Hospital-Wellcome Trust Research Unit (LOMWRU) in Lao PDR since 2019, Liz is conferred the title of Professor of Tropical Medicine. Stuart Blacksell - Senior Research Scientist based at the Mahidol-Oxford Tropical Medicine Research Unit (MORU) in Thailand, Stuart is conferred the title of Professor of Tropical Microbiology.
\n \n\n \n \n\n \n\n \n \n \n \n MORU Bangkok\n \n \n\n \n\n\n
\n \n\n \n28 October 2020
\n \n \n \nWe are pleased to announce that Prof Joel Tarning has been awarded the biennial Grahame-Smith Prize by the British Pharmacological Society for outstanding contributions to clinical pharmacology. Joel has headed MORU's Clinical Pharmacology Department since 2012. Since then, the Department has grown into large, productive group that conducts laboratory- and computer-based pharmacology research.
\n \n\n \n \n